ROC curve and P-R curve (attack traffic proportion = 50%). by Longyan Ran (18452261)

Effect of melatonin (50 μM) on the TGF-β1 (10 ng/mL, 72 h)-mediated TGF-β1/Smad pathway and EMT in HBdSMCs. by Yang Zhang (30734)

Scenario (6): Parameter variation (50% decrease)—With 5 N.m load applied at t = 0.3s. by Djaloul Karboua (16510091)

“…<p>Scenario (6): Parameter variation (50% decrease)—With 5 N.m load applied at t = 0.3s.…”

IC₅₀s data of antimalarials against controls. by Winnie Okore (14139712)

Subjects:

Expression of ApoB-50 decreased lipid accumulation and inhibited HCV production. by Bei Wang (116772)

Drugs IC₅₀s data during the study period. by Winnie Okore (14139712)

Subjects:

Transcriptional and translational markers of syncytialization and biochemical differentiation are significantly decreased by rotenone. by O’Llenecia S. Walker (8486163)

SNPs IC₅₀s data at codon 876 during the study period. by Winnie Okore (14139712)

Subjects:

Comparison of 6 virtues between the two groups [PCOS (n = 49); non-PCOS (n = 50)]. by Ghina Ghazeeri (766076)

The decrease in blood flow disrupts CV pruning. by Lin Wen (557398)

Test characteristics for identifying stenosis ≥ 50% in any limb from aorta till popliteal artery in the overall population (<i>n = 126 limbs</i>). by O. Stivalet (6890189)

Modeling methods of included studies (n = 61). by Natalie Riva Smith (13899600)

Subjects:

Association of polymorphic IC_50s versus wild<i>-</i>type at codon 876 in selected drugs tested. by Winnie Okore (14139712)

Subjects:

Average stiffness for the force range of 0–50 N. by Jihun Kim (10091)

Average stiffness for the force range of 50–100 N. by Jihun Kim (10091)

Antibody IC₅₀ (or pIC₅₀) and maximum neutralization of D614G and BA.1 pseudoviruses bearing different glycosylation and SARS-CoV-2 VLPs. by Sabrina Lusvarghi (2329267)

Populations and outcomes modeled in included studies (n = 61). by Natalie Riva Smith (13899600)

Subjects:

Decrease in vRNA in brain during antiretroviral therapy. by Sonny R. Elizaldi (9684796)

Sugar-sweetened beverage policies examined by simulation modeling studies (n = 61). by Natalie Riva Smith (13899600)

Subjects:

Olaparib reverses the oxLDL-mediated decrease in co-immunoprecipitation of IκBα with RelA or p50. by Khamis Mustafa (17941332)

“…(A) OxLDL decreased co-immunoprecipitation of IκBα with both RelA and p50, and olaparib reversed the effect of oxLDL on the dissociation of IκBα with RelA and p50. …”